Jiangsu Jibeier Pharmaceutical Full Year 2024 Earnings: Misses Expectations

Jiangsu Jibeier Pharmaceutical (SHSE:688566) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥896.5m (up 4.1% from FY 2023).
• Net income: CN¥218.9m (flat on FY 2023).
• Profit margin: 24% (down from 25% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: CN¥1.14 (down from CN¥1.17 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jiangsu Jibeier Pharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Jiangsu Jibeier Pharmaceutical is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.